Why Arbutus Biopharma stock plunged Tuesday

The FDA has notified via verbal communication regarding a clinical hold on Arbutus Biopharma Corporation's AB-101 Investigational New Drug (IND) application.
AB-101 is a novel, oral PD-L1 inhibitor designed to reawaken and boost the immune system of patients with chronic hepatitis B virus (cHBV).